The most recent high for the S&P qualified the market under a 'sell' criteria for my Investing Strategy. The last time this happened was in March-April 2012, when the index went on to shed nearly 11% from peak-to-trough by the time the market bottomed in June 2012. However, this should not be viewed as a clarion call to sell everything, but may instead offer a better opportunity to generate more »
With earnings season in full swing, you can capitalize on great value if you keep your eyes open. Stocks trade illogically or fundamentally change all the time following earnings, and in this article I am looking at three stocks that I’d buy after earnings on Monday.
Health Net (NYSE: HNT)
After a decade of flat trading, Health Net might not come to mind as a post-earnings stock to buy more »
In my Investing Strategy, I like to sniff around stocks which I have featured, when the S&P has experienced a period of selling. At current valuations, the S&P is at a point where I prefer to be lightening the load, or looking at setting up some covered calls to generate some funds. I had suggested some covered call opportunities on Feb. 1 around Tesoro Corporation (NYSE: TSO), Krispy more »
Last time we checked in on the health IT sector, it was on fire.
Some $19.2 billion in federal stimulus dollars were headed the sector's way, to be doled out based on completion of “meaningful use” requirements then being written by a committee of government and industry bureaucrats.
Medidata Solutions (NASDAQ: MDSO) is a Software-as-a-Service (SaaS) provider to enable life science companies design and manage clinical trials. The stock IPO'd in 2009 at $14 a share and a brief rally in 2010 was quickly snuffed out before a second rally took hold mid-2011. This rally took out its 52-week high and carried through to today. In the early phase of the rally, there was a high volume more »